Study of Debio 4126 for acromegaly patients on current therapy
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new medication, Debio 4126, for people with acromegaly who are already being treated with octreotide or lanreotide. The goal is to see if it can help control hormone levels and is safe to use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been taking octreotide or lanreotide for acromegaly for at least 6 months, and your dose has been steady for the past 12 weeks
- Your IGF-1 level is within the normal range at the screening visit
- You have not had pituitary surgery in the last 6 months or plan to during the study
- You do not have serious heart or blood vessel problems, like heart failure or stroke, within the past year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called MAR002 to treat acromegaly, a hormone disorder caused by a pituitary tumor that makes too much growth hormone. The drug is designed to help lower hormone levels and improve symptoms.
This study follows people with acromegaly to better understand how treatments are used in real life and how well they work over time. It may help improve future treatment choices by comparing outcomes across different care patterns.
This study watches how patients with acromegaly respond to octreotide, a medication given as injections under the skin. Researchers will collect information about how well the treatment works and any side effects you experience.
This early-phase trial tests a new investigational drug called MAR002 in healthy men. The goal is to see how safe the drug is and how the body handles it before moving to larger studies.
This trial studies how pasireotide LAR—a drug that controls growth hormone levels—affects bone health in people with acromegaly whose disease is not well-controlled after 6 months of another therapy. It may help patients understand the bone benefits of switching to this treatment.
This trial tests a long-acting form of octreotide, a medicine that lowers growth hormone levels, in people with active acromegaly. It aims to see if this treatment is safe and effective in controlling the disease.
Hear when a new Acromegaly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.